openPR Logo
Press release

Artificial Intelligence (AI) in Clinical Trials Market Size Report 2032: Transforming Drug Development with Next-Gen Technologies

10-07-2025 12:07 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Artificial Intelligence (AI) in Clinical Trials Market

Artificial Intelligence (AI) in Clinical Trials Market

DelveInsight's Artificial Intelligence (AI) in Clinical Trials Market Insights Report 2032 provides the current and forecast market analysis, individual leading Artificial Intelligence (AI) in Clinical Trials Companies market shares, challenges, Artificial Intelligence (AI) in Clinical Trials Market Drivers, barriers, trends, and key market Artificial Intelligence (AI) in Clinical Trials companies in the market.

To read more about the latest highlights related to the Artificial Intelligence (AI) in Clinical Trials Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Artificial Intelligence (AI) in Clinical Trials Market Report
• In May 2025, Avant Technologies, Inc. (OTCQB: AVAI) and JV partner Ainnova Tech, Inc. announced they have begun acquisition talks to strengthen their position in the evolving AI-driven healthcare market.
• In March 2025, Suvoda has launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle.
• The Artificial Intelligence in clinical trials market was valued at USD 1,350.79 million in 2024, growing at a CAGR of 12.04 % during the forecast period from 2025 to 2032 to reach USD 3,334.47 million by 2032
• The leading Artificial Intelligence (AI) in Clinical Trials Companies such as TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and others.
• North America is projected to hold the largest share of the Artificial Intelligence (AI) in Clinical Trials market in 2024, driven by several key factors.

To know more about why North America is leading the market growth in the Artificial Intelligence (AI) in Clinical Trials Market, get a snapshot @ Artificial Intelligence (AI) in Clinical Trials Market Outlook- https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Artificial Intelligence (AI) in Clinical Trials Market Dynamics
The growing prevalence of chronic diseases is expected to drive AI in clinical trial market growth. For instance, according to GLOBOCAN data from 2023, approximately 20 million new cancer cases were reported in 2022, with this number projected to rise to 32.6 million by 2045 around the world. As per the data from the World Health Organization (WHO) 2024, in the Eastern Mediterranean Region, over 788,000 cancer diagnoses were recorded in 2022. This figure is anticipated to double to approximately 1.57 million cases by 2045. According to data published by the British Heart Foundation 2024, approximately 640 million people globally were affected by heart and circulatory diseases, with these numbers anticipated to rise in the coming years. The same source notes that around 67 million individuals are diagnosed with heart or circulatory diseases each year.

Artificial Intelligence (AI) in Clinical Trials Market Segmentation Analysis
AI in Clinical Trials Market by Product (Software and Services), Technology (Machine Learning (ML), Natural Language Processing (NLP), and Others), Application (Clinical Trial Design & Optimization, Patient Identification & Recruitment, Site Identification & Trial Monitoring, and Others), Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others), End-User (Pharmaceutical & Biotechnology Companies and Medical Device Companies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Get a sneak peek at the Artificial Intelligence (AI) in Clinical Trials Market Dynamics @ Artificial Intelligence (AI) in Clinical Trials Market Dynamics Analysis- https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Artificial Intelligence (AI) in Clinical Trials Companies
TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and others.

Artificial Intelligence (AI) in Clinical Trials Market Drivers
The AI in Clinical Trials market is driven by the increasing global burden of chronic diseases such as diabetes, cardiovascular conditions, respiratory disorders, and cancer. This surge is further supported by rising investments and funding aimed at advancing drug discovery and development processes. Moreover, the growing trend of strategic collaborations and partnerships among pharmaceutical, biotechnology, and medical device companies is playing a crucial role in accelerating the adoption of AI-powered clinical trial solutions.

Which MedTech key players in the Artificial Intelligence (AI) in Clinical Trials Market are set to emerge as the trendsetter explore @ Artificial Intelligence (AI) in Clinical Trials Companies- https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Artificial Intelligence (AI) in Clinical Trials Market Report
• Coverage- Global
• Forecast Period- 2025-2032
• Artificial Intelligence (AI) in Clinical Trials Companies- TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and others.

Interested in knowing the Artificial Intelligence (AI) in Clinical Trials Market by 2032? Click to get a snapshot of the Artificial Intelligence (AI) in Clinical Trials Market Trends- https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Artificial Intelligence (AI) in Clinical Trials Market Report Introduction
2. Artificial Intelligence (AI) in Clinical Trials Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Artificial Intelligence (AI) in Clinical Trials Market Key Factors Analysis
6. Artificial Intelligence (AI) in Clinical Trials Market Porter's Five Forces Analysis
7. Artificial Intelligence (AI) in Clinical Trials Market Assessment
8. Artificial Intelligence (AI) in Clinical Trials Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Artificial Intelligence (AI) in Clinical Trials Market Size Report 2032: Transforming Drug Development with Next-Gen Technologies here

News-ID: 4211557 • Views:

More Releases from DelveInsight Business Research LLP

The Parkinson's Disease Market Size in the 7MM was ~USD 3,539 Million in 2025, and is projected to rise with a significant CAGR by 2034, estimates DelveInsight
The Parkinson's Disease Market Size in the 7MM was ~USD 3,539 Million in 2025, a …
DelveInsight's "Parkinson Disease Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Parkinson Disease, historical and forecasted epidemiology as well as Parkinson Disease therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Explore Parkinson Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from Parkinson Disease Market Report • On
Chronic Obstructive Pulmonary Disease Market Size in the 7MM is projected to grow at a CAGR of 6.3% by 2034, estimates DelveInsight
Chronic Obstructive Pulmonary Disease Market Size in the 7MM is projected to gro …
DelveInsight's "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as Chronic Obstructive Pulmonary Disease therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Explore Chronic Obstructive Pulmonary Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @
Atypical Hemolytic Uremic Syndrome Market Size in the 7MM was USD 1,300 million in 2023 which is expected to Rise by 2034, estimates DelveInsight
Atypical Hemolytic Uremic Syndrome Market Size in the 7MM was USD 1,300 million …
DelveInsight's "Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as Atypical Hemolytic Uremic Syndrome therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Explore Atypical Hemolytic Uremic Syndrome Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @
Osteogenesis Imperfecta Market Size in the 7MM was ~USD 30 million in 2023 and is projected to grow with a significant CAGR by 2034, estimates DelveInsight
Osteogenesis Imperfecta Market Size in the 7MM was ~USD 30 million in 2023 and i …
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Osteogenesis Imperfecta, historical and forecasted epidemiology as well as Osteogenesis Imperfecta therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Explore Osteogenesis Imperfecta Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from Osteogenesis Imperfecta Market Report • On

All 5 Releases


More Releases for Trial

Clinical Trial Investigative Site Network Market Clinical Trial Investigative Si …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Clinical Trial Investigative Site Network Market - (By Therapeutic Areas (Oncology, Cardiology, CNS, Pain Management, Endocrine, Others), By Phase (Phase I, Phase II, Phase III, Phase IV), By End-use (Sponsor, CRO)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034." According to the latest research by InsightAce Analytic, the Global Clinical Trial Investigative Site Network Market
Transformative Trends Impacting the Electronic Trial Master File (eTMF) Systems …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Electronic Trial Master File (eTMF) Systems Market Size By 2025? The market size of the electronic trial master file (eTMF) systems has experienced fast growth over recent years. The market is projected to increase from $1.36 billion in 2024 to $1.55 billion in 2025, with
Transformative Trends Impacting the Electronic Trial Master File (eTMF) Systems …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Electronic Trial Master File (eTMF) Systems Market Size By 2025? The market size of the electronic trial master file (eTMF) systems has experienced fast growth over recent years. The market is projected to increase from $1.36 billion in 2024 to $1.55 billion in 2025, with
Clinical Trial Management System
According to a new market report published by Persistence Market Research “Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019” the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019. Request Report TOC @ https://www.persistencemarketresearch.com/methodology/3017
Clinical Trial Logistics
Clinical Trial Logistics 16th to 17th May 2011, Marriott Regents Park, London, United Kingdom. It currently costs just over £500 million ($800 million) to bring a new chemical to market and development timelines continue to fall in the 10-15 year range. A key reason for high R&D costs is due to logistical failures including failure to recruit patients on time. A way to avoid this is to move clinical trials
Clinical Trial Logistics
Announcing SMi's 5th annual… Clinical Trial Logistics conference 16th and 17th May 2011, Central London, UK www.smi-online.co.uk/2011logistics-london6.asp It currently costs just over £500 million ($800 million) to bring a new chemical to market and development timelines continue to fall in the 10-15 year range. A key reason for high R&D costs is due to logistical failures including failure to recruit patients on time. A way to avoid this is to move clinical